348 related articles for article (PubMed ID: 30185782)
21. BH3 mimetics: status of the field and new developments.
Billard C
Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
[TBL] [Abstract][Full Text] [Related]
22. Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.
Mohana-Kumaran N; Hill DS; Allen JD; Haass NK
Pigment Cell Melanoma Res; 2014 Jul; 27(4):525-39. PubMed ID: 24655414
[TBL] [Abstract][Full Text] [Related]
23. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
24. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
Wang YF; Jiang CC; Kiejda KA; Gillespie S; Zhang XD; Hersey P
Clin Cancer Res; 2007 Aug; 13(16):4934-42. PubMed ID: 17652623
[TBL] [Abstract][Full Text] [Related]
26. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.
Jiang CC; Wroblewski D; Yang F; Hersey P; Zhang XD
Neoplasia; 2009 Sep; 11(9):945-55. PubMed ID: 19724688
[TBL] [Abstract][Full Text] [Related]
27. Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.
Koss B; Ryan J; Budhraja A; Szarama K; Yang X; Bathina M; Cardone MH; Nikolovska-Coleska Z; Letai A; Opferman JT
Oncotarget; 2016 Mar; 7(10):11500-11. PubMed ID: 26862853
[TBL] [Abstract][Full Text] [Related]
28. DRP-1 functions independently of mitochondrial structural perturbations to facilitate BH3 mimetic-mediated apoptosis.
Milani M; Beckett AJ; Al-Zebeeby A; Luo X; Prior IA; Cohen GM; Varadarajan S
Cell Death Discov; 2019; 5():117. PubMed ID: 31341643
[TBL] [Abstract][Full Text] [Related]
29. BH3 mimetic-elicited Ca
Ferdek PE; Jakubowska MA; Nicolaou P; Gerasimenko JV; Gerasimenko OV; Petersen OH
Cell Death Dis; 2017 Mar; 8(3):e2640. PubMed ID: 28252652
[TBL] [Abstract][Full Text] [Related]
30. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
Hauck P; Chao BH; Litz J; Krystal GW
Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
[TBL] [Abstract][Full Text] [Related]
31. Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells.
Mukherjee N; Reuland SN; Lu Y; Luo Y; Lambert K; Fujita M; Robinson WA; Robinson SE; Norris DA; Shellman YG
J Invest Dermatol; 2015 Mar; 135(3):842-850. PubMed ID: 25350317
[TBL] [Abstract][Full Text] [Related]
32. BH3-only proteins: possible proapoptotic triggers for melanoma therapy.
Plötz M; Eberle J
Exp Dermatol; 2014 Jun; 23(6):375-8. PubMed ID: 24673301
[TBL] [Abstract][Full Text] [Related]
33. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
34. Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity.
Wilson-Annan J; O'Reilly LA; Crawford SA; Hausmann G; Beaumont JG; Parma LP; Chen L; Lackmann M; Lithgow T; Hinds MG; Day CL; Adams JM; Huang DC
J Cell Biol; 2003 Sep; 162(5):877-87. PubMed ID: 12952938
[TBL] [Abstract][Full Text] [Related]
35. Bcl-2 family inhibitors sensitize human cancer models to therapy.
Valentini E; Di Martile M; Brignone M; Di Caprio M; Manni I; Chiappa M; Sergio I; Chiacchiarini M; Bazzichetto C; Conciatori F; D'Aguanno S; D'Angelo C; Ragno R; Russillo M; Colotti G; Marchesi F; Bellone ML; Dal Piaz F; Felli MP; Damia G; Del Bufalo D
Cell Death Dis; 2023 Jul; 14(7):441. PubMed ID: 37460459
[TBL] [Abstract][Full Text] [Related]
36. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.
Chen L; Willis SN; Wei A; Smith BJ; Fletcher JI; Hinds MG; Colman PM; Day CL; Adams JM; Huang DC
Mol Cell; 2005 Feb; 17(3):393-403. PubMed ID: 15694340
[TBL] [Abstract][Full Text] [Related]
37. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
38. BH3-only protein BIM: An emerging target in chemotherapy.
Shukla S; Saxena S; Singh BK; Kakkar P
Eur J Cell Biol; 2017 Dec; 96(8):728-738. PubMed ID: 29100606
[TBL] [Abstract][Full Text] [Related]
39. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance.
Pécot J; Maillet L; Le Pen J; Vuillier C; Trécesson SC; Fétiveau A; Sarosiek KA; Bock FJ; Braun F; Letai A; Tait SWG; Gautier F; Juin PP
Cell Rep; 2016 Dec; 17(12):3347-3358. PubMed ID: 28009301
[TBL] [Abstract][Full Text] [Related]
40. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
